191 related articles for article (PubMed ID: 30334904)
21. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
22. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
[TBL] [Abstract][Full Text] [Related]
23. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Piccardo A; Puntoni M; Lopci E; Conte M; Foppiani L; Sorrentino S; Morana G; Naseri M; Cistaro A; Villavecchia G; Fanti S; Garaventa A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1046-56. PubMed ID: 24562643
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.
Perel Y; Conway J; Kletzel M; Goldman J; Weiss S; Feyler A; Cohn SL
J Pediatr Hematol Oncol; 1999; 21(1):13-8. PubMed ID: 10029806
[TBL] [Abstract][Full Text] [Related]
26.
Turnock S; Turton DR; Martins CD; Chesler L; Wilson TC; Gouverneur V; Smith G; Kramer-Marek G
Sci Rep; 2020 Dec; 10(1):20918. PubMed ID: 33262374
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
Messina JA; Cheng SC; Franc BL; Charron M; Shulkin B; To B; Maris JM; Yanik G; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2006 Dec; 47(7):865-74. PubMed ID: 16444675
[TBL] [Abstract][Full Text] [Related]
28. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
30. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.
Sharp SE; Trout AT; Weiss BD; Gelfand MJ
Radiographics; 2016; 36(1):258-78. PubMed ID: 26761540
[TBL] [Abstract][Full Text] [Related]
31. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo.
Brans B; Laureys G; Schelfhout V; Wiele CV; Potter CR; Dhooge C; Simons M; Dierckx RA
Eur J Nucl Med; 1998 Feb; 25(2):144-9. PubMed ID: 9473262
[TBL] [Abstract][Full Text] [Related]
32. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
33. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
34. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
35. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
Yanik GA; Parisi MT; Shulkin BL; Naranjo A; Kreissman SG; London WB; Villablanca JG; Maris JM; Park JR; Cohn SL; McGrady P; Matthay KK
J Nucl Med; 2013 Apr; 54(4):541-8. PubMed ID: 23440556
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
37. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
Taggart D; Dubois S; Matthay KK
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):403-18. PubMed ID: 19088694
[TBL] [Abstract][Full Text] [Related]
38. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
39. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
40. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy.
Boubaker A; Bischof Delaloye A
Q J Nucl Med; 2003 Mar; 47(1):31-40. PubMed ID: 12714952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
